KPTIbenzinga

Karyopharm Expects 2025 Sales Of $140M-$155M Versus Consensus Of $160.55M, With US Xpovio Net Product Revenue Expected To Be $115M-$130M

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on February 19, 2025 by benzinga